The AsepticSure™ hospital sterilisation system is portable, affordable and can be used by trained maintenance staff. It is placed in the centre of the room to be cleaned. Vents and doors are then sealed with an easily and cleanly removable 3M-tape product.
The system is turned on from outside of the room through a remote wireless computer interface. The room is filled with a unique and patented gas formula that is ozone-based to specific humidity and charge strength.
Following the charge period, the sterilisation process is remotely turned off and a separate technology is employed that restores the atmosphere inside the room to Environmental Protection Agency (EPA) standards. The end result leaves the treated room sterile of pathogens with a sweet, fresh oxygen-charged atmosphere very similar to what you experience after a thunderstorm.
From an operational perspective, the turnaround time for re-use of rooms up to 113 cubic metres in size is 80 to 90 minutes. This includes the decontamination of carpets, drapes and medical equipment, all to the 6 log sterilisation standard.
Current research is being conducted at Medizone’s dedicated Bio Safety Level 2A (BSL2A) certified laboratories located at Queen’s University in Kingston, Ontario, Canada and is under the direction of Dr. Michael E. Shannon, former Director General Laboratory Center for Disease Control, Health Canada.
The laboratory is located in the heart of one of the finest bio-medical communities in Canada and is providing a primary research and development platform for the Corporation as it proceeds down what is now a clear path to commercialisation with its lead product, AsepticSure™.
Given the outstanding range of bactericidal kill rates achieved to date with the pathogens most often associated with hospital derived infections (including Tuberculosis), it has become clear there are opportunities to expand scientific horizons through collaborative arrangements in many diverse and exciting new applications.
Medizone is currently preparing for large-scale hospital beta testing at sites in both Canada and the United States (with at least one of these trials to be conducted at a veterinary hospital). Given the performance of its patented system in earlier large-scale mock-up trials, the outcome of the upcoming trials should be of no surprise.
Accordingly, the AsepticSure system is expected to significantly reduce the incidence of nosocomial infections, a number which now exceeds 1.7 million in the US annually (Centers for Disease Control and Prevention (CDC), 2007).
Based on recent CDC cost-estimates, modest predictions of AsepticSure performance would see hospitals saving US$6 to US$7 for each US$1 invested in this technology through reduced costs associated with prolonged admissions, re-admissions, expanded use of antibiotics and expensive ICU care.
In a proposal to the US Senate by the Infectious Diseases Society of America (Jan 2009) it was argued that "State and local public health departments are unable to maintain their capacity to adequately address emerging infectious disease threats in community and healthcare settings.
Such settings include tracking and treating specific organisms such as methicillin-resistant Staphylococcus Aureus (MRSA) which are becoming endemic in many settings; Clostridium difficile infections which are on the rise; and multidrug resistant strains of the so-called “gram negative” types of bacteria for which few treatments exist".
Large room mock-up trials by Medizone's research team at Queen's University have not found a pathogen to date (gram negative or gram positive, anaerobic or aerobic) which does not succumb to the AsepticSure decontamination system. This, in essence, equates to ICU or surgical suite sterilization (> 6 log reduction) achieved in 90 minutes or less, with no health risk to staff or threat to the environment.
Successful completion of the first phase of AsepticSure beta testing at Hotel Dieu Hospital, an ambulatory care teaching and research hospital affiliated with Queen’s University in Kingston, Ontario, Canada was completed in late 2010.
Pre-inoculated stainless steel test discs as well as carpet swatches (typically found in many health care facilities) were placed in selected locations to assess for antimicrobial effects.
Not only were 100% of the MRSA and C. difficile spores eliminated from the stainless steel discs (7.1 logs bacterial kill for MRSA and 6.2 log bacterial kill for C difficile spores), the pathogens were also completely eliminated from all contaminated carpet samples - something unachievable with any other technology we are aware of.
The AsepticSure system has proven to be able to achieve a very high level of sustainable microbial kill to the sterilisation standard of >6 log (99.9999%) and was the subject of a major peer review article published in the American Journal Of Infection Control in December, 2011. It was also the recipient of a prestigious innovation award from The World Health Organization's ICPIC Conference in Geneva, in July, 2011.
AsepticSure TM is a safe, highly efficacious room disinfection system that sets the gold standard worldwide for hospital and laboratory decontamination. Its powerful antimicrobial action is achieved through a patented process involving the interaction of low-dose hydrogen peroxide (1%) and ozone (80 PPM) at a specific relative humidity for a fixed period of time.
For an overview of its technical and efficacy specifications, download our AsepticSure Datasheet PDF file.
|Organism||Ozone (PPM)||H202 (%)||Exposure (min)||Microbial Kill (Log10)|
|C. difficile spores||80||1||15-30||6.1|
|B. subtilis spores||80||1||30||6.1|
|Carbapenem-resistant Enterobacteriaceae (CRE)||80||1||30||7.0|